1. Home
  2. BNR vs UNCY Comparison

BNR vs UNCY Comparison

Compare BNR & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$9.05

Market Cap

179.7M

Sector

Health Care

ML Signal

HOLD

Logo Unicycive Therapeutics Inc.

UNCY

Unicycive Therapeutics Inc.

HOLD

Current Price

$6.94

Market Cap

145.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNR
UNCY
Founded
2014
2016
Country
China
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
179.7M
145.3M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
BNR
UNCY
Price
$9.05
$6.94
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$25.67
AVG Volume (30 Days)
14.5K
661.2K
Earning Date
06-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$675,000.00
Revenue This Year
$111.65
N/A
Revenue Next Year
N/A
$582.86
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.95
$0.47
52 Week High
$41.72
$8.74

Technical Indicators

Market Signals
Indicator
BNR
UNCY
Relative Strength Index (RSI) 26.83 41.89
Support Level $7.99 $6.17
Resistance Level $9.70 $7.22
Average True Range (ATR) 1.19 0.54
MACD -0.50 -0.10
Stochastic Oscillator 6.87 5.83

Price Performance

Historical Comparison
BNR
UNCY

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

About UNCY Unicycive Therapeutics Inc.

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Share on Social Networks: